MicroPort® Access Receives Approvals for Angiography Guidewire and Angiography Catheter in Brazil

Brasilia, Brazil – August 2020 - Shanghai MicroPort® Access MedTech Co., Ltd. (“MicroPort® Access”) is pleased to announce it has recently received regulatory approvals for its Angiography Guidewire and Angiography Catheter from ANVISA of Brazil.

 

The Angiography Guidewire and Angiography Catheter are both key devices required in the percutaneous coronary intervention (PCI) procedure that plays a major role in the diagnosis and treatment of coronary heart disease (CHD).  The Angiography Guidewire enables access to vessels using percutaneous techniques to assist with both diagnoses and deployment of therapeutic interventional devices, such as stents. After insertion of the Angiography Guidewire into vessels, the Angiography Catheter works alongside the Guidewire to facilitate the angiographic checks undertaken as part of the PCI procedure.

 

Prior to approval in Brazil, the two devices had been successfully launched in China and have become well-established in surgical practice.

 

The Angiography Guidewire is the result of a collaboration between doctors and engineers.  Adopting the pioneering guidewire tip structure allows the distal end of both the main wire and coil wire to be smaller. This significantly improves the device’s maneuverability in challenging cases where anatomical structures are heavily complex.  The Angiography Catheter offers surgeons most common 5F and 6F specifications required in angiography procedures whilst also providing both left and right support type for additional flexibility.

 

Jiahong Tan the President of MicroPort® CardioFlow commented, “Previously, MicroPort® Access had received approvals for its Inflation Device, Y Connector, Pressure Monitoring Tubings, and Manifolds in Brazil.  These latest approvals for Angiography Guidewire and Angiography Catheter lay a solid groundwork for the company’s further expansion in the South American market. These devices are also well-suited to be used along with the Firehawk® Rapamycin Target Eluting Coronary Stent System developed by MicroPort®.  Collectively the MicroPort® devices will provide an improved integrated PCI therapeutic solution for doctors and their patients”.